Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
OncoImmunology is Scopus-indexed (Q1, CiteScore 12.1), WoS SCIE, DOAJ. It is covered by India's One Nation One Subscription scheme, which pays the article processing charge for authors at eligible institutions. Published by Taylor and Francis Ltd..
Checked against the index lists dated .
ISSN 2162-4011Verify ISSN ↗2162-402XVerify ISSN ↗
Publisher: Taylor and Francis Ltd.
Cost to publish: APC covered for authors at ONOS-subscribed Indian institutions
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 41 / 428 | 90th | Q1 |
| Immunology and Allergy | 31 / 234 | 86th | Q1 |
| Immunology | 35 / 243 | 85th | Q1 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription)
Yes — actively indexed in Scopus, coverage 2012–present, best quartile Q1, CiteScore 12.1.
OncoImmunology is Q1 in Oncology (rank 41 of 428), Q1 in Immunology and Allergy (rank 31 of 234) and Q1 in Immunology (rank 35 of 243), by CiteScore 2025.
OncoImmunology is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 12.1, which places it in quartile Q1 at the 90th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 2.438, quartile Q1, with an H-index of 134.
For authors at Indian institutions covered by One Nation One Subscription (ONOS), the article processing charge is paid by the scheme. The publisher lists an article processing charge of about US$2,913 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
OncoImmunology is published by Taylor and Francis Ltd. Its print ISSN is 2162-4011 and its online ISSN is 2162-402X.
Yes. ONOS also covers its article processing charge for authors at eligible institutions.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
OncoImmunology has an h-index of 153 and a 2-year mean of 6.36 citations per paper (OpenAlex). Its Scopus CiteScore is 12.1, quartile Q1. On 2-year citations it ranks #35 of 424 Scopus journals in Oncology.
OncoImmunology published 120 papers in 2025; its busiest recent year was 2017 with 437. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2025–2026), authors are most often from United States (20.7%), France (11.4%) and Germany (11.3%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 2 retracted papers are recorded (0.5 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.